Cipla API facility in Bengaluru gets EIR from USFDA
Cipla had earlier said that USFDA issued seven observations after conducting a routine 'CGMP inspection' at Cipla's API manufacturing facility in Virgonangar, Bengaluru.
NEW DELHI: Cipla Ltd on Sunday announced the closure of inspection by the US health regulator at the company's API manufacturing facility in Bengaluru.
"Following the inspection by the United States Food and Drug Administration (USFDA) at Company's API manufacturing facility in Virgonagar, Bengaluru, from July 15- 19, 2019, the company has received the Establishment Inspection Report (EIR), indicating closure of the inspection," the company said in a filing to the BSE.
Read Also: Cipla arm, Novartis enter agreement for Ultibro Breezhaler to treat COPD
The company had earlier said that USFDA issued seven observations after conducting a routine 'CGMP inspection' at Cipla's API manufacturing facility in Virgonangar, Bengaluru.
Read Also: Cipla, Stempeutics ink licensing deal for Stempeucel-DFU to treat a diabetic foot ulcer
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd